Cargando…

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) and fibrobl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuki, Masahiro, Hoshi, Taisuke, Yamamoto, Yuji, Ikemori‐Kawada, Megumi, Minoshima, Yukinori, Funahashi, Yasuhiro, Matsui, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010799/ https://www.ncbi.nlm.nih.gov/pubmed/29733511 http://dx.doi.org/10.1002/cam4.1517

Ejemplares similares

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
por: Matsuki, Masahiro, et al.
Publicado: (2017)

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
por: Tohyama, Osamu, et al.
Publicado: (2014)

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
por: Finn, Richard S., et al.
Publicado: (2021)

Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model
por: Nakazawa, Youya, et al.
Publicado: (2015)

Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
por: Ichikawa, Kenji, et al.
Publicado: (2020)

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
por: Kimura, Takayuki, et al.
Publicado: (2018)

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
por: Yamamoto, Yuji, et al.
Publicado: (2014)

Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15
por: Dong, Gang, et al.
Publicado: (2018)

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2020)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Zhu, Jie, et al.
Publicado: (2021)

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8(+) T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
por: Kato, Yu, et al.
Publicado: (2019)

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma
por: Suoh, Maito, et al.
Publicado: (2020)

Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma
por: Fianco, Giulia, et al.
Publicado: (2017)

MPDZ promotes DLL4-induced Notch signaling during angiogenesis
por: Tetzlaff, Fabian, et al.
Publicado: (2018)

Palmitoylated SCP1 is targeted to the plasma membrane and negatively regulates angiogenesis
por: Liao, Peng, et al.
Publicado: (2017)

Correction: Palmitoylated SCP1 is targeted to the plasma membrane and negatively regulates angiogenesis
por: Liao, Peng, et al.
Publicado: (2017)

Effects of RhoC downregulation on the angiogenesis characteristics of myeloma vascular endothelial cells
por: Zhao, Zhihua, et al.
Publicado: (2019)

Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor‐4 inhibition in hepatocellular carcinoma
por: Iseda, Norifumi, et al.
Publicado: (2022)

Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
por: Barrett, Richard Lee, et al.
Publicado: (2020)

Epithelial–mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy
por: Rojas‐Puentes, Leonardo, et al.
Publicado: (2016)

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
por: Nakagawa, Takayuki, et al.
Publicado: (2014)

Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis
por: Vervoort, Stephin J, et al.
Publicado: (2018)

Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis
por: Wu, Sheng, et al.
Publicado: (2012)

BACH1 promotes the progression of esophageal squamous cell carcinoma by inducing the epithelial–mesenchymal transition and angiogenesis
por: Zhao, Yan, et al.
Publicado: (2021)

Isolation of cancer‐associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma
por: Sha, Meng, et al.
Publicado: (2018)

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
por: Croft, Wayne, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

Evolution of fibroblasts in the lung metastatic microenvironment is driven by stage-specific transcriptional plasticity
por: Shani, Ophir, et al.
Publicado: (2021)

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
por: Adachi, Yusuke, et al.
Publicado: (2022)

FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma
por: Zhong, Cheng‐Qian, et al.
Publicado: (2018)

Cancer‐associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
por: Zhang, Aibin, et al.
Publicado: (2017)

Cancer‐associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer
por: Aizawa, Takashi, et al.
Publicado: (2019)

Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts
por: Bhagat, Tushar D, et al.
Publicado: (2019)

Identification of the prognostic value of elevated ANGPTL4 expression in gallbladder cancer‐associated fibroblasts
por: Wang, Fang‐Tao, et al.
Publicado: (2021)

Overexpression of DRAM enhances p53-dependent apoptosis
por: Takahashi, Masahiro, et al.
Publicado: (2013)

NOTCH3 limits the epithelial–mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer
por: Matsuura, Norihiro, et al.
Publicado: (2021)

Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer
por: Li, Xiang, et al.
Publicado: (2019)

Differentiated glioma cell-derived fibromodulin activates integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth
por: Sengupta, Shreoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_39ilpcjqb7rm2ene0ig8h3vmkj